Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Human Plasma-Derived Therapeutics Industry: Supply and Demand, Markets and Prices 2021-2027

Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Human Plasma-Derived Therapeutics Market Status and Forecast (2016-2027)
      • 1.3.2 Global Human Plasma-Derived Therapeutics Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Human Plasma-Derived Therapeutics Supply by Company

    • 2.1 Global Human Plasma-Derived Therapeutics Sales Value by Company
    • 2.2 Human Plasma-Derived Therapeutics Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Human Plasma-Derived Therapeutics Market Status by Category

    • 3.1 Human Plasma-Derived Therapeutics Category Introduction
      • 3.1.1 Albumin
      • 3.1.2 Immunoglobulin
      • 3.1.3 Clotting Factor
      • 3.1.4 Prothrombin Complex
      • 3.1.5 Others
    • 3.2 Global Human Plasma-Derived Therapeutics Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Human Plasma-Derived Therapeutics Market Status by End User/Segment

    • 4.1 Human Plasma-Derived Therapeutics Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
      • 4.1.3 Research Center
    • 4.2 Global Human Plasma-Derived Therapeutics Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Human Plasma-Derived Therapeutics Market Status by Region

    • 5.1 Global Human Plasma-Derived Therapeutics Market by Region
    • 5.2 North America Human Plasma-Derived Therapeutics Market Status
    • 5.3 Europe Human Plasma-Derived Therapeutics Market Status
    • 5.4 Asia Pacific Human Plasma-Derived Therapeutics Market Status
    • 5.5 Central & South America Human Plasma-Derived Therapeutics Market Status
    • 5.6 Middle East & Africa Human Plasma-Derived Therapeutics Market Status

    6 North America Human Plasma-Derived Therapeutics Market Status

    • 6.1 North America Human Plasma-Derived Therapeutics Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Human Plasma-Derived Therapeutics Market Status

    • 7.1 Europe Human Plasma-Derived Therapeutics Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Human Plasma-Derived Therapeutics Market Status

    • 8.1 Asia Pacific Human Plasma-Derived Therapeutics Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Human Plasma-Derived Therapeutics Market Status

    • 9.1 Central & South America Human Plasma-Derived Therapeutics Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Human Plasma-Derived Therapeutics Market Status

    • 10.1 Middle East & Africa Human Plasma-Derived Therapeutics Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Human Plasma-Derived Therapeutics Market Forecast by Category and by End User/Segment

    • 12.1 Global Human Plasma-Derived Therapeutics Sales Value Forecast (2022-2027)
    • 12.2 Global Human Plasma-Derived Therapeutics Forecast by Category
    • 12.3 Global Human Plasma-Derived Therapeutics Forecast by End User/Segment

    13 Global Human Plasma-Derived Therapeutics Market Forecast by Region/Country

    • 13.1 Global Human Plasma-Derived Therapeutics Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Takeda
      • 14.1.1 Company Information
      • 14.1.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.1.3 Takeda Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Sanquin
      • 14.2.1 Company Information
      • 14.2.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.2.3 Sanquin Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Prometic Life Sciences
      • 14.3.1 Company Information
      • 14.3.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.3.3 Prometic Life Sciences Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Octapharma
      • 14.4.1 Company Information
      • 14.4.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.4.3 Octapharma Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Kedrion
      • 14.5.1 Company Information
      • 14.5.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.5.3 Kedrion Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Grifols
      • 14.6.1 Company Information
      • 14.6.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.6.3 Grifols Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Gammagard
      • 14.7.1 Company Information
      • 14.7.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.7.3 Gammagard Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Entegrion, Inc.
      • 14.8.1 Company Information
      • 14.8.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.8.3 Entegrion, Inc. Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 CSL Behring
      • 14.9.1 Company Information
      • 14.9.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.9.3 CSL Behring Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Baxter
      • 14.10.1 Company Information
      • 14.10.2 Human Plasma-Derived Therapeutics Product Introduction
      • 14.10.3 Baxter Human Plasma-Derived Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Alkahest

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Human Plasma-Derived Therapeutics market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Human Plasma-Derived Therapeutics market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Albumin
      Immunoglobulin
      Clotting Factor
      Prothrombin Complex
      Others

      Segmented by End User/Segment
      Hospital
      Clinic
      Research Center

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Takeda
      Sanquin
      Prometic Life Sciences
      Octapharma
      Kedrion
      Grifols
      Gammagard
      Entegrion, Inc.
      CSL Behring
      Baxter
      Alkahest

      Buy now